Category: Artificial Intelligence

Artificial Intelligence is reshaping prostate cancer care, from more accurate screening and early detection to optimizing treatment strategies. New research highlights four major clinical areas where AI is already making a measurable difference in diagnosis, risk assessment, and therapy planning. keep reading

AI in medicine is advancing rapidly, but who decides if it truly improves care? JAMA’s summit report calls attention to the urgent need for better standards, smarter oversight, and genuine collaboration so that AI benefits aren’t just promised—they’re proven. keep reading

The FDA has approved ArteraAI Prostate, an innovative AI tool trained on thousands of biopsy images and clinical data, to help assess the risk of prostate cancer progression and personalize treatment plans. Doctors and patients can now benefit from faster, more accurate risk predictions. keep reading

Long waits for a prostate MRI can cause anxiety and delay treatment decisions. A new AI tool is designed to help doctors quickly identify which patients need scans most urgently, so they don’t lose valuable time in their cancer care journey. keep reading

A new review of 19 studies shows that adding artificial intelligence to biparametric MRI improves its ability to detect clinically significant prostate cancer. With high sensitivity and specificity, AI helps bpMRI approach the accuracy of more complex scans without requiring contrast agents. keep reading

When facing a prostate cancer diagnosis, knowing how aggressive the disease is makes all the difference in treatment choices. A new large-scale study shows that Artificial Intelligence, working with MRI scans, may help predict tumor grade with surprising accuracy—promising more clarity for patients and their doctors. keep reading

Today’s multiparametric MRI (mpMRI) has revolutionized the prostate cancer (PCa) world. Thanks to its high resolution, 3-dimensional imaging done by a powerful 3 Tesla (3T) magnet, experienced radiologists are able to identify areas that are suspicious for clinically significant PCa (csPCa). This helps avoid unnecessary biopsies, but if a biopsy is indicated, the area can keep reading

When a patient is told, “You have prostate cancer,” it’s not a simple one-size-fits-all diagnosis. The doctor will then give the patient an idea of how severe his cancer is. If his prostate cancer (PCa) is still localized (that is, contained within the gland), the doctor will specify if it is low, intermediate, or high keep reading

The interpretation of medical images is “a task that lies at the heart of the radiologist’s work.”[i] In fact, the human element—a radiologist’s eyes and brain—is just as important as what a high resolution, 3- dimensional image depicts. Imaging types include x-ray, MRI, CT scan, ultrasound and PET scan, but no matter how advanced the keep reading

We’ve posted numerous blogs on the contributions of Artificial Intelligence (AI) to various aspects of MRI detection and diagnosis of prostate cancer (PCa). We’ve reported AI’s ability to predict metastasis, assign Gleason scores and PI-RADS scores, pinpoint tumor margins for focal therapy, rule out need for biopsy, predict PCa metastasis, and more—showing the accuracy and keep reading